VIDEO: ‘Real world’ data for patients with HER2-positive, BRCA1/2 breast cancer
In this video, Elias Obeid, MD, MPH, discussed treatment patterns and clinical outcomes of patients with germline BRCA1/2-mutated, HER2-positive advanced breast cancer.
Obeid, interim chief of the division of breast medical oncology and director of the Breast, Ovarian, and Prostate Cancer Risk Assessment Program at Fox Chase Cancer Center and assistant professor in the department of genetics at Temple University, presented the data at this year’s virtual San Antonio Breast Cancer Symposium.
“We wanted to look at what is happening in the real world for patients who have this diagnosis of metastatic HER2-positive breast cancer associated with germline BRCA 1 and 2 mutation,” he explained.
Collapse
Obeid E. Poster PS10-53. Presented at: San Antonio Breast Cancer Symposium (Virtual); Dec. 8-11, 2020